ANALYSIS-How cannabis is firing up investors & the US supply chain

Published 05-APR-2019 14:43 P.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

NEW YORK, April 4 (Reuters) - US companies cannot stop talking about marijuana, hoping in part they can catch investor interest as the booming economy around the drug lifts revenues throughout the supply chain writes David Randall.

With the recreational use of cannabis now legal in 10 states and the District of Columbia and medical marijuana legal in 23 states, marijuana is on its way to becoming an $80 billion industry in the United States by 2030, according to estimates by Cowen Inc. That outsized growth is starting to bleed into adjacent industries ranging from energy to packaging to point-of-sale technology whose products are used in the production or sale of marijuana. As investors circle the cannabis space, supply-chain companies are showing a new willingness to associate themselves with an industry that remained largely illegal a decade ago.

Cryogenic equipment manufacturer Chart Industries Inc told analysts on Feb. 14 that "cannabis has double-digit growth potential for us" as more grow houses use liquefied carbon dioxide in the extraction of marijuana. Point of sale company Socket Mobile Inc said on Feb. 13 that cannabis dispensaries are "ideally suited to iPad-based point-of-sale solutions for accounting and regulatory compliance." And private security company Brinks Co said on Feb. 6 that its North America segment should have "another strong year" due in part to the growth of the cannabis industry.

"You're starting to see a repurposing of the supply chain and that could give some companies another leg of growth," said Chris Retzler, a portfolio manager of the Needham Growth fund. "This has the potential to drive revenues higher and lead to some earnings surprises."

How big a boost

In a sense, many companies are looking to replicate the strategy of lawn and garden products company Scotts Miracle-Gro Co, which has transformed itself over the last four years into a player in the cannabis industry by focusing on the sales of lighting, fertilizer and growing systems specifically for marijuana. Shares of the company, which acquired a competitor in hydroponics for $450 million in 2018, are up nearly 30% for the year to date, a rally about double that of the benchmark S&P 500.

But just how much revenue will come from cannabis-related sales into businesses that are further afield from the plant remains unclear.

For supply chain companies like Chart Industries, revenue from cannabis "realistically could be a couple of percentage points a year," said Pavel Molchanov, an analyst at Raymond James.

Yet that does not mean it will be insignificant, he said.

"In the Gold Rush it was the people who were making the picks and shovels for gold miners that made the most money. This is a case of a company that has absolutely nothing to do with cannabis historically, yet it's benefiting from the picks-and-shovels opportunity," he said.

Jillian Evanko, the chief executive of Chart, told Reuters in an interview that cannabis is now the fastest-growing segment of its business, and that the company has undisclosed products in its pipeline made specifically for use in the marijuana industry.

"Historically we did not focus on these markets, but now we have dedicated teams both commercially and technical (engineering/product development) to develop these markets further," she said.

No longer open secret

The outsized investor interest in cannabis and growing recognition of cannabis as a therapeutic drug may prompt more company management teams to openly discuss how their products are used by the marijuana industry in hopes of attracting shareholders, said Brett Hundley, an analyst at Seaport Global.

Some, like alcoholic beverage company Constellation Brands Inc and tobacco company Altria Group Inc, are making investments into the cannabis industry to proactively move into an industry that poses a threat to their existing business lines, he said.

Yet others are starting to discuss cannabis as a way to tap in to changing attitudes toward marijuana, Hundley said.

"I was on a Balchem conference call a few weeks ago and we asked the company if they were considering getting into cannabis, and the CEO talked about how we've been supplying minerals to grow houses," he said. "I literally watched the stock jump 2% from the time I asked the question to the time he answered it. Anything associated with cannabis today is getting an increase in market value."

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free